<DOC>
	<DOCNO>NCT02764151</DOCNO>
	<brief_summary>This study evaluate safety tolerability increase dos PF-06840003 patient malignant glioma .</brief_summary>
	<brief_title>First Patient Study PF-06840003 Malignant Gliomas</brief_title>
	<detailed_description />
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Astrocytoma</mesh_term>
	<mesh_term>Oligodendroglioma</mesh_term>
	<criteria>Diagnosis WHO Grade IV glioblastoma WHO Grade III anaplastic glioma For patient Grade IV GBM , recurrent disease time first second recurrence progression . For patient Grade III anaplastic glioma , recurrent disease time least first recurrence fourth recurrence progression Karnofsky performance score great equal 70 % Adequate bone marrow , kidney liver function History CNS bleed within 6 month registration Previous antiangiogenics antivascular endothelial growth factor within 12 month registration Requires treatment high dose systemic corticosteroid define &gt; 2 mg/day Radiation therapy within 12 week registration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>GBM</keyword>
	<keyword>malignant glioma</keyword>
	<keyword>glioma</keyword>
	<keyword>anaplastic glioma</keyword>
	<keyword>astrocytoma</keyword>
	<keyword>IDO</keyword>
	<keyword>IDO1</keyword>
	<keyword>PF-06840003</keyword>
</DOC>